Literature DB >> 8969638

Pre beta 1-high-density lipoprotein increases in coronary artery disease.

T Miida1, Y Nakamura, K Inano, T Matsuto, T Yamaguchi, T Tsuda, M Okada.   

Abstract

Pre beta 1-HDL promotes cholesterol efflux from cell membranes. Its plasma concentration is regulated by lecithin: cholesterol acyltransferase (LCAT). To clarify whether the concentration of pre beta 1-HDL changes in coronary artery disease (CAD), we determined the distribution of apolipoprotein A-I (apoA-I) among HDL subfractions in 20 CAD patients and 20 healthy controls, using nondenaturing two-dimensional gel electrophoresis. We found that CAD patients had significantly higher concentrations of pre beta 1-HDL than the controls [7.6% +/- 3.4% vs 4.6% +/- 2.3% of apoA-I (P < 0.01)]. Even after correcting for apoA-I concentrations, this increase remained significant [87 +/- 37 vs 63 +/- 28 mg/L apoA-I (P < 0.05)]. The mean LCAT concentration was significantly lower (P < 0.05) in CAD patients than in controls. These findings, that pre beta 1-HDL concentrations increase in CAD, strongly suggest that the process of reverse cholesterol transport could be altered in CAD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8969638

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  12 in total

1.  Influence of HDL particles on cell-cholesterol efflux under various pathological conditions.

Authors:  Bela F Asztalos; Katalin V Horvath; Michael Mehan; Yuya Yokota; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2017-04-18       Impact factor: 5.922

2.  High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol.

Authors:  Amar A Sethi; Maureen Sampson; Russell Warnick; Nehemias Muniz; Boris Vaisman; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Alan T Remaley
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

3.  Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease.

Authors:  Beatriz Talayero; Liyun Wang; Jeremy Furtado; Vincent J Carey; George A Bray; Frank M Sacks
Journal:  J Lipid Res       Date:  2014-06-25       Impact factor: 5.922

4.  Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Authors:  Bela F Asztalos; Dorothea Collins; Katalin V Horvath; Hanna E Bloomfield; Sander J Robins; Ernst J Schaefer
Journal:  Metabolism       Date:  2008-01       Impact factor: 8.694

5.  Associations of genetic variants in ATP-binding cassette A1 and cholesteryl ester transfer protein and differences in lipoprotein subclasses in the multi-ethnic study of atherosclerosis.

Authors:  Michael Y Tsai; Na Li; A Richey Sharrett; Steven Shea; David R Jacobs; Russell Tracy; Donna Arnett; Valerie Arends; Wendy Post
Journal:  Clin Chem       Date:  2009-01-08       Impact factor: 8.327

6.  High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk.

Authors:  Bela F Asztalos; Katalin V Horvath; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

7.  Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women.

Authors:  Stefania Lamon-Fava; David M Herrington; David M Reboussin; Michelle Sherman; Katalin Horvath; Ernst J Schaefer; Bela F Asztalos
Journal:  Atherosclerosis       Date:  2008-12-24       Impact factor: 5.162

Review 8.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.

Authors:  Xavier Rousset; Boris Vaisman; Marcelo Amar; Amar A Sethi; Alan T Remaley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

9.  Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors.

Authors:  Tomas Vaisar; Jennifer L Gordon; Jake Wimberger; Jay W Heinecke; Alan L Hinderliter; David R Rubinow; Susan S Girdler; Katya B Rubinow
Journal:  J Clin Lipidol       Date:  2020-11-24       Impact factor: 4.766

10.  Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease.

Authors:  Mark S Borja; Bradley Hammerson; Chongren Tang; Olga V Savinova; Gregory C Shearer; Michael N Oda
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.